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Abstract
Background: Although Kabul city, Afghanistan, is currently the worldwide largest focus of
cutaneous leishmaniasis (CL) with an estimated 67,500 cases, donor interest in CL has been
comparatively poor because the disease is non-fatal. Since 1998 HealthNet TPO (HNTPO) has
implemented leishmaniasis diagnosis and treatment services in Kabul and in 2003 alone 16,390 were
treated patients in six health clinics in and around the city. The aim of our study was to calculate
the cost-effectiveness for the implemented treatment regimen of CL patients attending HNTPO
clinics in the Afghan complex emergency setting.
Methods: Using clinical and cost data from the on-going operational HNTPO program in Kabul,
published and unpublished sources, and discussions with researchers, we developed models that
included probabilistic sensitivity analysis to calculate ranges for the cost per disability adjusted life
year (DALY) averted for implemented CL treatment regimen. We calculated the cost-effectiveness
of intralesional and intramuscular administration of the pentavalent antimonial drug sodium
stibogluconate, HNTPO's current CL 'standard treatment'.
Results: The cost of the standard treatment was calculated to be US$ 27 (95% C.I. 20 – 36) per
patient treated and cured. The cost per DALY averted per patient cured with the standard
treatment was estimated to be approximately US$ 1,200 (761 – 1,827).
Conclusion: According to WHO-CHOICE criteria, treatment of CL in Kabul, Afghanistan, is not
a cost-effective health intervention. The rationale for treating CL patients in Afghanistan and
elsewhere is discussed.
Background
In terms of global burden of disease the leishmaniases are
the third most important vector-borne disease [1]. Kabul
city is currently the world-wide largest focus of cutaneous
leishmaniasis (CL) with an estimated 67,500 new cases
per annum [2]. Due to its potentially disfiguring pathol-
ogy, i.e. gross cutaneous lesions that appear at the biting
site of the insect vector, the disease has a significant social
impact on the affected population (e.g. women with
lesions are deemed unsuitable for marriage or to raise
children) [3]. However, because the disease is non-fatal,
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interest by donor agencies to prevent and control the dis-
ease has been comparatively poor.
The non-governmental organization (NGO) HealthNet
TPO (HNTPO; formerly HealthNet International) has
been providing leishmaniasis diagnosis and treatment in
Kabul since 1995, the date when the first reports of an
imminent CL epidemic emerged [4]. HNTPO's current
leishmaniasis activities are embedded in a large, nation-
wide operational program (Malaria and Leishmaniasis Con-
trol Program, Afghanistan) and are focusing on CL micro-
scopic diagnosis and treatment, prevention and control
(e.g. through the distribution of insecticide-treated nets to
active patients and health education).
In the past decade global humanitarian assistance by the
international community on complex emergencies has
increased to >US$4.5 billion in 2004, of which 8.5% was
spent on the provision of health care [5]. Nevertheless,
emergencies repeatedly show that there is a shortage of
funds, especially for long-term reconstruction efforts [6].
Critics argue that this funding shortfall is because donor
agencies are reluctant to support programs with poor
records of impact evaluation. The sheer volume of
resources spent on humanitarian aid and the chronicity of
many emergencies call for more attention to be paid to the
issue of 'value for money', i.e. how to best allocate limited
resources to maximize health outcomes.
Cost-effectiveness analyses (CEA) have become a tool that
can assist priority setting for health interventions in devel-
oping countries, not only by measuring the impact of a
particular intervention but also in developing targeted
strategies as well as comparing different approaches to
treatment. Effectiveness of a given health intervention is
usually measured in terms of disability adjusted life years
(DALY) averted, a measure of health outcome incorporat-
ing premature death and morbidity, or disability [7].
Since the massive humanitarian re-construction efforts
began after the fall of the Taliban in 2002, Afghanistan is
slowly emerging from two decades of civil war. Neverthe-
less, country health indicators are still among the worst
globally [8] with many preventable diseases such as polio,
typhoid fever and measles rampant throughout the coun-
try [9]. Despite >US$2.2 billion having been spent on the
Afghan health sector since 2002 [5], there has -so far- only
been one published study evaluating the cost-effective-
ness of a specific health intervention, i.e. a latrine revision
program implemented by the International Committee of
the Red Cross [10].
The aim of the work reported here was two-fold. Our first
aim was to estimate the cost-effectiveness of HNTPO's
operational leishmaniasis treatment program in Kabul,
Afghanistan (i.e. the comparator being no treatment given
to CL patients). Our second aim was to discuss potential
policy implications of our results for CL treatment in
Afghanistan and elsewhere, especially as CEA for CL pre-
vention and control strategies have not been carried
before. Additionally, we highlight characteristics associ-
ated with CEA of health programs in complex emergency
environments.
Methods
Study site and leishmaniasis treatment
Following a widely publicized appeal by the World Health
Organization (WHO) [11], HNTPO received funds to
expand its leishmaniasis activities in Kabul from one
clinic to four fixed health centers and one mobile clinic
serving five different locations in and around Kabul; these
clinics exclusively treat CL patients. In 2003 HNTPO
treated a total 16,390 CL patients at these sites, which
according to HNTPO and Afghan Ministry of Health
(MoH) estimates represented 75% of all CL cases treated
in Kabul.
Patients attending HNTPO leishmaniasis treatment cent-
ers were treated with the pentavalent antimonial drug
sodium stibogluconate (SSG), either given intralesionally
(up to five 2 – 5 ml injections given every 5 – 7 days) or
intramuscularly (20 mg/kg bodyweight for 21 consecutive
days). Pentavalent antimonial drugs (SbV) are the stand-
ard WHO-recommended anti-leishmanial treatment in
Afghanistan [12] and elsewhere [13].
Program costs and clinical parameters
The analyses were based on HNTPO clinic (e.g. patient
and staff numbers, underlying demographic and clinical
patient characteristics), program and cost figures in 2003.
Costs were primarily obtained from one-year HNTPO
budgets approved by international donors and corre-
sponding expenditure reports by HNTPO's accounting
department. Other costs were obtained from price cata-
logues and consultations with researchers and program
managers. An ingredients approach was used with costs
being divided according to standardized methods into
staff time, project management, medical, transportation,
equipment, communication and administrative overhead
costs [14]. All costs were in 2003 US$.
The cost of HNTPO's 'standard treatment' was estimated
by multiplying the total number of patients treated in
HNTPO clinics in 2003, i.e. 16,390, with the average
amount of drug used per patient, the purchase cost of a 30
ml vial of generic SSG (Albert David, Calcutta, India) and
non-medical and medical operational costs as incurred in
2003.
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Each HNTPO treatment centre is manned by five health
staff (i.e. one medical doctor, one patient registrar, three
nurses), working a total 18,000 man-hrs per year. In 2003,
83% and 17% of all patients attending HNTPO clinics
were treated with intralesional and intramuscular SSG,
respectively. From HNTPO's drug store data we calculated
that a total 90 ml and 13 ml of SSG are used when treating
patients intramuscularly and intralesionally, respectively
(i.e. these figures include drug wastage if new SSG bottles
had to be opened when treating new patients).
Outcome measures
Effectiveness was calculated in terms of DALY averted. For
non-fatal diseases, the DALY equals the years of healthy
life lost due to the disability (i.e. leishmaniasis) [7], which
is the product of leishmaniasis incidence (i.e. 16,390), the
standardized disability weight for CL (i.e. 0.023) [15] and
the duration of the disease. The duration of disease was
arbitrarily set to 12 months following discussion with
HNTPO clinicians, which is close to the mean duration of
disease observed in a large prevalence survey (i.e. 9.1
months) [2]; unfortunately data on the natural course of
L. tropica infection does not exist. DALY were discounted
at 3%, but they were not weighted for age, because there
is controversy over the quantitative impact of the age-
weighting function used for burden of disease calcula-
tions [16].
Data on treatment effectiveness and compliance for differ-
ent treatment regimens were obtained from a recent rand-
omized, controlled clinical trial in Kabul [17] and from
work carried out elsewhere [18-21]. In the absence of bet-
ter evidence, we assumed a linear relation between treat-
ment compliance and effectiveness in each case, such that
zero compliance results in zero effectiveness, and the
degree in compliance achieved in the trial resulted in trial
decreases in morbidity. If data was not available, we esti-
mated parameter values based on our operational field
experience in Afghanistan and discussions with fellow col-
leagues.
Our cost effectiveness outputs were based on probabilistic
sensitivity analyses [22]. DALY averted due to treatment
were combined with costs of each intervention. To allow
for a high degree of uncertainty and variability surround-
ing the variables, probability distributions were assigned
to model inputs, i.e. published or estimated values of
treatment efficacy and compliance. The distributions were
modeled according to Monte Carlo simulations (outputs
were based on 5,000 iterations) using @risk software
(Palisade Corporation, Newfield, NY) in Microsoft Excel
(Microsoft Corporation, Seattle, Washington) spread-
sheets, where the software generates the distribution of
possible cost-effectiveness ratios by recalculating the
spreadsheet for each additional iteration, each time using
different randomly selected sets of values from the proba-
bility distributions of the input variables. This allows cost-
effectiveness outputs to be expressed as a probability dis-
tribution rather than as a single point estimate. We calcu-
lated the mean and range in which 95% of the cost-
effectiveness ratio fell (i.e. the cost-effectiveness range) as
summary indicators.
HNTPO is a registered NGO in Afghanistan and the oper-
ational program activities described in the manuscript
had ethical clearance by the Afghan Ministry of Public
Health.
Results
Program costs
Non-medical and medical costs for HNTPO's leishmania-
sis treatment activities are presented in Table 1. Excluding
medical costs, program costs as incurred by HNTPO in
2003 were US$ 129,820. Medical costs to cover the
16,390 patients treated at HNTPO clinics in 2003 were
US$ 102,224. Including 7% administrative HNTPO over-
head costs, estimated operational costs were approxi-
mately one quarter million US$.
Clinical input parameters and DALY
Patient numbers included in our analyses are represented
in Figure 1. Modeled clinical parameters are presented in
Table 2. The burden of disease of patients attending
HNTPO clinics was estimated to be 377 DALY. Because of
all patients only a fraction complied with treatment and
cured, only 214 DALY were averted due to successful treat-
ment of patients (Figure 1).
Per patient treatment costs
Using the number of observed patient numbers (i.e.
16,390) treated per year, program costs (Table 1), and the
HNTPO standard treatment's estimated efficacy and com-
pliance (Table 2), the cost per patient treated and cured in
2003 with the reference treatment was US$ 26.7 (95% CI
19.9 – 35.9).
The cost per DALY averted with HNTPO's standard treat-
ment was estimated at US$ 1180.5 (95% CI: 760.6 –
1826.9).
Figure 2 represents the change in cost per DALY averted
when one of the model input parameters is reduced or
increased, as specified.
Discussion
We estimated the cost-effectiveness of an operational CL
treatment program in Kabul, Afghanistan. This was done
for internal program evaluation purposes (i.e. to assess
program impact), but also to yield comparative data that
would be of use for the local MoH and other health sector
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NGOs and stakeholders. Such data and exercises are rare
[10], despite repeated calls for health interventions in
complex emergencies to be evidence-based and assessed
for their cost-effectiveness [23-25]. In our approach we
extrapolate results from published clinical research trials
to a defined operational setting, estimating the cost-effec-
tiveness of the currently used combination of intrale-
sional and intramuscular SSG in Kabul, Afghanistan (i.e.
'standard treatment'). We express results as realistic ranges
rather than simple point estimates, thereby including the
uncertainty surrounding used input parameters.
The cost-effectiveness of current leishmaniasis treatment 
in Kabul, Afghanistan and its comparison to alternative 
treatment protocols
Using chosen input parameters, we estimate that the cur-
rent cost per patient treated and cured in HNTPO's opera-
tional program in Kabul is US$ 27. The cost per patient
treated and cured with SSG we report here was lower than
expected, and is much lower than the SbV treatment costs
reported in other CL-endemic countries, notably US$ 280
in Guatemala [26], US$ 300 in Peru [27], and US$ 5500
in the USA. (Aronson, pers. comm.). This outcome is due
to the difference in drug purchasing price (e.g. use of
generic versus branded SbV [Pentostam® or Glucan-
time®]), therapy protocol (e.g. intralesional versus intra-
muscular versus intravenous administration of SbV),
labor costs (e.g. Afghan versus American health staff), and
patient care (i.e. treatment is on an out-patient basis in
Afghanistan versus an in-patient basis in the USA.).
For the first time, the cost-effectiveness of CL treatment is
evaluated. Using parameter estimates listed in Table 1 we
estimate that the cost-effectiveness of CL treatment in
Kabul is approximately US$ 1,200 per DALY averted.
Policy implications for cutaneous leishmaniasis treatment 
in Kabul and elsewhere
According to WHO-CHOICE criteria health interventions
are 'very cost-effective' and 'cost-effective' if within one
and three times a country's per capita GDP, respectively
[28]. The per capita GDP for Afghanistan was US$ 165 in
2004 and US$ 232 in 2006 [29]. Hence, with US$ 1,200
per DALY averted CL treatment in Kabul is not a 'cost-
effective' health intervention, and based on above criteria
it cannot be argued that it is a justified health expenditure.
Although the methods to estimate an intervention's cost-
effectiveness may not be strictly comparable, we can set
our figures into context, with other CEA having found the
cost-effectiveness of supplemental tetanus immunization
in Pakistan to be US$ 2 – 6 per DALY averted [30], melar-
soprol treatment for late stage African trypanosomiasis in
Uganda US$ 8 [31], SSG treatment for fatal visceral leish-
maniasis US$18 [32], ivermectin distribution for
onchocerciasis control US$ 14 – 30 [33], malaria chloro-
Table 1: One-year non-medical and medical program costs to treat cutaneous leishmaniasis in Kabul, Afghanistan in 2003.
Item Total Cost (US$)
Non-Medical Costs
Expatriate Staff 38,880.00
National Staff 39,780.00
Transport 10,800.00
Tools and Equipment 7,740.00
Communication 3,120.00
Operational 28,500.00
Sub-total 128,820.00
Medical Costs
Patient record forms [@US$0.1 pp] 1,639.00
Laboratory materials for drug administration [@US$ 0.5 pp visit] 63,265.40
Sodium stibogluconate [@US$ 3 per vial; 12,440 vials used] 37,320.03
Sub-Total 102,224.43
7% Administrative Overhead Cost 16,173.11
Total Program Cost 247,217.54
Listed are costs for all human and operational resources directly involved in leishmaniasis treatment activities as implemented in Kabul by 
HealthNet TPO (HNTPO). Costs for these resources were derived from proposals approved by donors as well as corresponding expenditures as 
reported by HNTPO's accounting department. The cost of the sodium stibogluconate is based on patient treatment regimens outlined in Materials 
and Methods. Abbreviation: Pp, per person. The full cost breakdown is available from the authors.
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quine chemoprophylaxis US$ 14 – 93 [22], integrated
water supply and sanitation US$ 20 – 1,152 [34], and the
mass-treatment of trachoma patients with azythromycin
US$ 9,000 – 65,000 [35].
In many leishmaniasis-endemic countries, the standard
recommended treatment for CL is the intramuscular
administration with SbV [13]. Had patients been treated
with intramuscular SSG only, 6,492 patients could have
been treated due to available staff man-hrs (i.e. due to the
higher number of patient-clinic visits required when fol-
lowing this regimen), which would have yielded an esti-
mate of US$ 3,718 per DALY averted (data not shown).
Clearly, in those countries increased use of intralesional
SbV as treatment regimen as in HNTPO's operational pro-
gram would increase the cost-effectiveness of anti-leish-
manial treatment dramatically.
However, whilst our analyses appear to demonstrate that
CL treatment in Kabul is not cost-effective according to
WHO-CHOICE criteria, several caveats of our analysis
have to be highlighted. First, as with any CEA, some of the
model input parameters are debatable. For example, we
arbitrarily chose a lesion duration of 12 months even
though many patients can have lesions of longer duration
[2]; undeniably, by doing so, we may have underesti-
mated true lesion duration due to L. tropica infection. As
shown in Figure 2, a longer lesion duration can have a sig-
nificant impact on the cost-effectiveness ratio. Unfortu-
nately, we are unaware of any published data on the
natural course of L. tropica infections, and used data rep-
resents our best estimate. Similarly, data used for clinical
efficacy in our evaluation has been extrapolated from
studies on two SbV, i.e. meglumine antimoniate and SSG.
No data has been published demonstrating that both
drugs have varying degree of efficacy in treating CL and
used data, again, represents our best estimate of mini-
mum and maximum values of the treatment efficacy dis-
tribution.
Second, as has been the case for schistosomiasis [36] and
other communicable diseases [37], the disability weight-
ing for CL as set by the Global Burden of Disease study
[7,15] is debatable and should be re-evaluated. CL can
cause significant scarring as well as chronic pathology,
which in some cultural contexts such as Afghanistan can
lead to severe ostracism of the affected population [3],
especially when scars are located on the face. In such
Table 2: Selected clinical variables for compared treatment protocols.
Probability Distribution Simulation Output Reference
Treatment Efficacy
'Standard Treatment' Triangular 0.70 Kabul estimate 0.701 Estimated from 17
0.93 [Maximum] Estimated from 18 and 20
0.48 [Minimum] Estimated from 19 and 21
Intralesional SbV (a) Triangular 0.75 Kabul estimate 0.721 17†
0.91 [Maximum] 18†
0.50 [Minimum] 19‡
Intramuscular SbV (b) Triangular 0.45 Kabul estimate 0.604 17
1.00 [Maximum] 20†
0.36 [Minimum] 21‡
Treatment Compliance
'Standard Treatment' Triangular 0.74 Kabul estimate 0.824 Estimated from 17
1.00 [Maximum] Estimate, not based on data
0.74 [Minimum] Estimated from 17
Intralesional SbV (d) Triangular 0.76 Kabul estimate 0.840 17
1.00 [Maximum] Estimate, not based on data
0.76 [Minimum] 17
Intramuscular SbV (e) Triangular 0.62 Kabul estimate 0.750 17
1.00 [Maximum] Estimate, not based on data
0.62 [Minimum] 17
Duration of disease (years) 1.000 Estimate, not based on data
Parameter distribution was simulated as described using @risk software. The triangular distribution was used to describe clinical parameter 
distributions. This is standard practice in cost-effectiveness analyses22 to estimate parameter inputs for which the variation is known (minimum and 
maximum estimates, Kabul estimate), but for which the precise nature of the distribution is not. Parameter estimates were taken from published 
clinical trials evaluating treatment alternatives for cutaneous leishmaniasis (minimum and maximum estimates) with data from HealthNet TPO's 
operational program in Kabul (Kabul estimate)17 being our 'best guess' and, hence, mode of the distribution. a, b, d, e refer to parameter estimates 
used in Figure 1. Drug efficacy estimates came from studies evaluating the therapeutic efficacy of pentavalent antimonial drugs (SbV) for cutaneous 
leishmaniasis, i.e. sodium stibogluconate (†) or meglumine antimoniate (‡)
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instances, DALY should not only be estimated for the
duration of active leishmaniasis lesions, but for the dura-
tion of scars as well. Inclusion of disability incurred due to
leishmaniasis scars in our DALY estimates would have sig-
nificantly altered our estimated cost-effectiveness range.
Thus, a disability weight similar to a cleft lip (i.e. 0.049),
Bancroftian filariasis (i.e. 0.106) or debilitating leprosy
(i.e. 0.152) [15], the cost-effectiveness of CL treatment in
Kabul would have been US$ 541, US$ 250, and US$ 174
per DALY averted, respectively (see also Figure 2).
Third, once patients cure from leishmaniasis they tend to
be immune to re-infection [38]. Thus, unlike other infec-
tious diseases such as dengue or malaria there will be no
recurrent DALY or treatment costs per person.
Fourth, CL in Kabul is transmitted anthroponotically with
active cases presumed to be highly infectious to sandfly
vectors [4]. Although epidemiological data investigating
the impact of mass treatment on anthroponotic CL trans-
mission does not exist, it is likely that treating and curing
leishmaniasis patients will reduce the size of the reservoir
and therefore avert further new cases (i.e. DALY). How
many cases would be prevented by treating one active case
is difficult to quantify, but it would reduce the cost-effec-
tiveness ratio.
Fifth, it is clear that our study only applies to the given,
local conditions in Kabul, with analyses being based on
chosen input parameters and care should be given not to
generalize the conclusions. Cost figures were primarily
Flow diagram of cost-effectiveness analysis evaluating different treatment options for cutaneous leishmaniasis in Kabul, Afghan-istanigure 1
Flow diagram of cost-effectiveness analysis evaluating different treatment options for cutaneous leishmaniasis 
in Kabul, Afghanistan. Represented are the number of patients that were diagnosed, treated and cured in HealthNet TPO's 
operational leishmaniasis program activities in 2003. Letters represent rates of cure and compliance, as modelled in Table 2.
CL patients 
attend clinic
Disease is confirmed clinically 
and parasitologically 
N = 16390 
Sodium Stibogluconate
Intralesional
n = 13604 
Cure
n = 8237 
Sodium Stibogluconate
Intramuscular
n = 2786 
(1- a)dad
Cure
n = 1262
(1- b)ebe
Non-cure
n = 1524
Non-cure
n = 5367
DALY averted
28
DALY averted 
186
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based on an operational program implemented locally
and are likely to vary when compared to programs else-
where.
In future work we plan to carry out a range of sensitivity
analyses to investigate the effect of a range of cost and clin-
ical parameters on estimated treatment cost-effectiveness.
For example, cost-effectiveness ratios would have been
higher had estimates been based on fewer patients attend-
ing the clinics.
Whilst it is clear that not all patients can be treated with
intralesional SbV (e.g. due to the painful route of drug
administration patients with lesions close to the eyes or
lips tend to be given intramuscular SbV instead) our
results show that costs to treat CL patients could be sub-
stantially reduced were a treatment strategy implemented
that would largely adopt the localized treatment of CL
lesions.
Difficulties associated with cost-effectiveness analyses in 
complex emergencies
It is surprising that cost-effectiveness analyses of health
interventions in complex emergencies are very scarce
[10,32], highlighting a major gap in the evidence-based
implementation of humanitarian programs [23]. Whilst it
is true that there are many logistical constraints in collect-
ing reliable financial and operational data in complex
emergencies (e.g. due to the absence of established health
information systems) [39], health interventions in these
settings are often vertical with program-allocated budgets
allowing for easy data collection. CEA should enable local
stakeholders to set health intervention priorities, use
results as leverage to obtain funding as well as make
implementing partners more accountable in front of
donor organizations. The drawback is that the CEA will be
based on local circumstances, which can vary considera-
bly between and within emergencies. However, it is clear
that within a local context, CEA will assist priority setting
Tornado diagram of the impact of variation of model input parameters on cost-effectiveness estimates for cutaneous leishma-niasis treatment in Kabul, AfghanistanFigure 2
Tornado diagram of the impact of variation of model input parameters on cost-effectiveness estimates for 
cutaneous leishmaniasis treatment in Kabul, Afghanistan. Tornado diagram showing how cost-effectiveness of cutane-
ous leishmaniasis treatment would change if one of the input parameters would be reduced or increased, as specified.
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of health interventions, whether for comparative pur-
poses between different diseases or a single disease [40].
Thus, for example, despite the findings reported here,
HNTPO's treatment activities currently implemented in
Kabul are still substantially more cost-effective than a
household latrine revision intervention to reduce
diarrheal disease [10].
Conclusion
Because CL is not fatal, it is largely ignored by interna-
tional aid and donor agencies, and it has become one of
the so-called 'neglected diseases'. Our results do little in
refuting this belief, as we demonstrate that the standard,
WHO-recommended treatment of CL in Afghanistan is -
according to WHO-CHOICE criteria- not cost-effective.
Efforts should be made to develop and standardize short
systemic treatment regimens for CL as well as to develop
regimens of localized treatment alternatives (e.g. intrale-
sional SSG) which may improve cost-effectiveness.
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